Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)

Core Viewpoint - Revelation Biosciences Inc. is set to present new clinical data on the therapeutic benefits of Gemini for treating acute kidney injury (AKI) and chronic kidney disease (CKD) at an upcoming conference, highlighting significant improvements in patient conditions [1] Group 1: Clinical Data Presentation - The presentation will include additional positive data from the recently completed PRIME Clinical Study [1] - The conference will take place at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) in San Diego from March 29 to April 1, 2026 [1] - The data demonstrates normalization of the hyperinflammatory state in stage 3 and 4 CKD patients [1] Group 2: Therapeutic Benefits - The presented data indicates a restoration of immunocompetence in patients with CKD [1]